PLD3 is accumulated on neuritic plaques in Alzheimer's disease brains

Alzheimer's Research and Therapy

Volumn 6, Issue 9, 2014, Pages

  Satoh, Jun Ichi ^a   Kino, Yoshihiro ^a   Yamamoto, Yoji ^a   Kawana, Natsuki ^a   Ishida, Tsuyoshi ^b   Saito, Yuko ^c   Arima, Kunimasa ^d  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b 1 7 1 Kohnodai   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d Komoro Kogen Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHOLIPASE D; PHOSPHOLIPASE D3; PROGRANULIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIOINFORMATICS; BRAIN CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULAR CELL; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOLECULAR INTERACTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENILE PLAQUE; SEQUENCE HOMOLOGY; SHY DRAGER SYNDROME; WESTERN BLOTTING;

EID: 84920853683     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0070-5     Document Type: Article

References (37)

1. Ghebranious N, Mukesh B, Giampietro PF, Glurich I, Mickel SF, Waring SC, McCarty CA: A pilot study of gene/gene and gene/environment interactions in Alzheimer disease. Clin Med Res 2011, 9:17-25.
2. Rosenthal SL, Kamboh MI: Late-onset Alzheimer's disease genes and the potentially implicated pathways. Curr Genet Med Rep 2014, 2:85-101.
3. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
4. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis Group: REM2 variants in Alzheimer's disease. N Engl J Med 2013, 368:117-127.
5. Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D, Levitch D, Hsu S, Choi J, Ryten M, UK Brain Expression Consortium, Hardy J, Ryten M, Trabzuni D, Weale ME, Ramasamy A, Smith C, Sassi C, Bras J, Gibbs JR, Hernandez DG, Lupton MK et al: Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 2014, 505:550-554.
6. Jenkins GM, Frohman MA: Phospholipase D: a lipid centric review. Cell Mol Life Sci 2005, 62:2305-2316.
7. Klein J: Functions and pathophysiological roles of phospholipase D in the brain. J Neurochem 2005, 94:1473-1487.
8. Oliveira TG, Di Paolo G: Phospholipase D in brain function and Alzheimer's disease. Biochim Biophys Acta 2010, 1801:799-805.
9. Kanfer JN, Hattori H, Orihel D: Reduced phospholipase D activity in brain tissue samples from Alzheimer's disease patients. Ann Neurol 1986, 20:265-267.
10. Singh IN, McCartney DG, Kanfer JN: Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells. FEBS Lett 1995, 365:125-128.
11. Brandenburg LO, Konrad M, Wruck C, Koch T, Pufe T, Lucius R: Involvement of formyl-peptide-receptor-like-1 and phospholipase D in the internalization and signal transduction of amyloid beta 1-42 in glial cells. Neuroscience 2008, 156:266-276.
12. Kanaho Y, Funakoshi Y, Hasegawa H: Phospholipase D signalling and its involvement in neurite outgrowth. Biochim Biophys Acta 2009, 1791:898-904.
13. Cai D, Netzer WJ, Zhong M, Lin Y, Du G, Frohman M, Foster DA, Sisodia SS, Xu H, Gorelick FS, Greengard P: Presenilin-1 uses phospholipase D1 as a negative regulator of β-amyloid formation. Proc Natl Acad Sci U S A 2006, 103:1941-1946.
14. Liu Y, Zhang YW, Wang X, Zhang H, You X, Liao FF, Xu H: Intracellular trafficking of presenilin 1 is regulated by β-amyloid precursor protein and phospholipase D1. J Biol Chem 2009, 284:12145-12152.
15. Lee MJ, Oh JY, Park HT, Uhlinger DJ, Kwak JY: Enhancement of phospholipase D activity by overexpression of amyloid precursor protein in P19 mouse embryonic carcinoma cells. Neurosci Lett 2001, 315:159-163.
16. Oliveira TG, Chan RB, Tian H, Laredo M, Shui G, Staniszewski A, Zhang H, Wang L, Kim TW, Duff KE, Wenk MR, Arancio O, Di Paolo G: Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits. J Neurosci 2010, 30:16419-16428.
17. Pedersen KM, Finsen B, Celis JE, Jensen NA: Expression of a novel murine phospholipase D homolog coincides with late neuronal development in the forebrain. J Biol Chem 1998, 273:31494-31504.
18. Munck A, Böhm C, Seibel NM, Hashemol Hosseini Z, Hampe W: Hu-K4 is a ubiquitously expressed type 2 transmembrane protein associated with the endoplasmic reticulum. FEBS J 2005, 272:1718-1726.
19. Satoh JI, Kino Y, Kawana N, Yamamoto Y, Ishida T, Saito Y, Arima K: TMEM106B expression is reduced in Alzheimer's disease brains. Alzheimers Res Ther 2014, 6:e17.
20. Mirra SS, Gearing M, McKeel DW Jr, Crain BJ, Hughes JP, van Belle G, Heyman A: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
21. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112:389-404.
22. COXPRESdb. [coxpresdb.jp]
23. Obayashi T, Okamura Y, Ito S, Tadaka S, Motoike IN, Kinoshita K: COXPRESdb: a database of comparative gene coexpression networks of eleven species for mammals. Nucleic Acids Res 2013, 41:D1014-D1020.
24. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, Sims KB, Lewis J, Lin WL, Dickson DW, Dahl HH, Bahlo M, Berkovic SF: Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 2012, 90:1102-1107.
25. Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, Pickut BA, Van den Broeck M, Mattheijssens M, Peeters K, Schymkowitz J, Rousseau F, Martin JJ, Cruts M, De Deyn PP, Van Broeckhoven C: Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 2008, 71:656-664.
26. Viswanathan J, Mäkinen P, Helisalmi S, Haapasalo A, Soininen H, Hiltunen M: An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:747-750.
27. Pickford F, Marcus J, Camargo LM, Xiao Q, Graham D, Mo JR, Burkhardt M, Kulkarni V, Crispino J, Hering H, Hutton M: Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am J Pathol 2011, 178:284-295.
28. Pereson S, Wils H, Kleinberger G, McGowan E, Vandewoestyne M, Van Broeck B, Joris G, Cuijt I, Deforce D, Hutton M, Van Broeckhoven C, Kumar-Singh S: Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J Pathol 2009, 219:173-181.
29. Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, Grossman M, Van Deerlin VM, Trojanowski JQ, Lee VM: Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet 2008, 17:1349-1362.
30. Walker LC, Waddell N, Ten Haaf A, kConFab Investigators, Grimmond S, Spurdle AB: Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers. Breast Cancer Res Treat 2008, 112:229-236.
31. Osisami M, Ali W, Frohman MA: A role for phospholipase D3 in myotube formation. PLoS One 2012, 7:e33341.
32. Almeida S, Zhou L, Gao FB: Progranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteins. PLoS One 2011, 6:e26454.
33. Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, Ballabio A: Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet 2011, 20:3852-3866.
34. Hu F, Padukkavidana T, Vægter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM: Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 2010, 68:654-667.
35. Dall'Armi C, Hurtado-Lorenzo A, Tian H, Morel E, Nezu A, Chan RB, Yu WH, Robinson KS, Yeku O, Small SA, Duff K, Frohman MA, Wenk MR, Yamamoto A, Di Paolo G: The phospholipase D1 pathway modulates macroautophagy. Nat Commun 2010, 1:e142.
36. PolyPhen-2. [http://genetics.bwh.harvard.edu/pph2/dbsearch.shtml]
37. Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V, Trojanowski JQ, Lee VM: TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 2012, 32:11213-11227.